カテゴリー： 世界, 医療/バイオ, MarketsandMarkets

世界のエピジェネティクス市場（～2028年）：製品・サービス別（酵素（DNA修飾酵素）、キット・試薬（抗体）、機器、ソフトウェア）、方法別（DNAメチル化）、技術別（NGS、PCR、質量分析）、用途別（腫瘍学、免疫学）

【英語タイトル】Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) - Global Forecast to 2028

MarketsandMarketsが出版した調査資料（BT2775-24）・商品コード：BT2775-24
・発行会社（調査会社）：MarketsandMarkets
・発行日：2023年12月20日
・ページ数：353
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：バイオ
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

“世界のエピジェネティクス市場規模は2023年の18億米ドルから2028年には43億米ドルに達し、予測期間中のCAGRは18.3％になると予測”シーケンスのコストと時間の削減と相まって研究開発への投資が増加していること、エピジェネティクス研究に対する政府の取り組みや資金援助による支援、エピジェネティクス研究のための技術の進歩、エピジェネティクスに基づく治療薬への関心の高まりなどの要因が挙げられます。

“キット＆試薬セグメントはエピジェネティクス市場でリード的なシェアを保持”
製品・サービスに基づき、世界のエピジェネティクス市場はキット＆試薬、酵素、機器・付属品、ソフトウェア、サービスに区分されます。キット＆試薬セグメントは大きなCAGRで成長すると予測されています。エピジェネティクス研究の急速な拡大と、市場参加者による費用対効果が高く使いやすいキットの導入は、市場の成長にプラスの影響を与えそうです。

“DNAメチル化分野が2022年にメソッド分野で最大シェアを占める”
メソッドに基づいて、エピジェネティクス市場は、DNAメチル化、ヒストン修飾、および他のメソッドにセグメント化されます。2022年、エピジェネティクス市場で最大のシェアを占めたのはDNAメチル化セグメント。DNAメチル化技術はがん研究に有効であるため、同分野は市場で圧倒的なシェアを占めています。

“アジア太平洋はエピジェネティクス市場でより速いペースで成長する可能性が高い”
エピジェネティクス市場の地域は、北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカに区分されます。アジア太平洋は、予測期間中に大きなCAGRで成長すると予測されています。同地域の成長の主な原動力は、発展途上のアジア太平洋経済圏における医療インフラの強化であり、現地の業界プレーヤーが追求する戦略的パートナーシップ、提携、合意、事業拡大がこれに加わります。

本レポートのために実施した一次インタビューは以下のように分類されます：
- 回答者別 供給側：60％、需要側：40％
- 回答者の役職別（供給側） 管理職：45％、CXOおよび取締役：30％、経営幹部：25％
- 地域別 北米：40％、ヨーロッパ：27％、アジア太平洋：20％、中南米：10％、中東・アフリカ：3％

レポート掲載企業一覧は以下の通りです：
- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Illumina, Inc. (US)
- PacBio (US)
- Abcam plc (UK)
- Active Motif, Inc. (US)
- Bio-Rad Laboratories Inc. (US)
- Promega Corporation (US)
- Revvity (US)
- Qiagen (Germany)
- New England Biolabs (US)
- Zymo Research Corporation (US)
- Diagenode SA(US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- EpiGentek Group Inc. (US)
- EpiCypher (US)
- Fios Genomics (UK)
- GenomeScan (Netherlands)
- Creative Biogene (US)
- BPS Bioscienc Inc (US)
- Abnova Corporation (Taiwan)
- Creative Diagnostics (US)
- Biomodal (UK)
- Integrated DNA Technologies Inc. (US)
- Novogene Co Ltd (China)

調査範囲：
本レポートはエピジェネティクス市場の詳細な情報を提供します。技術、タイプ、疾患適応、投与経路、エンドユーザー、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの企業プロフィールや最近の動向、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点：
本レポートは、エピジェネティクス市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー／新規参入者を支援します。また、利害関係者が競争状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのにも役立ちます。本レポートは、利害関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します：
- 主要な促進要因（研究開発投資の増加、シーケンスコストと時間の減少、エピジェネティクス研究に対する有利な政府の取り組みと資金提供、エピジェネティクス研究における技術的進歩、エピジェネティクスに基づく治療薬に対する需要の高まり）、阻害要因（毒性学におけるエピゲノムデータの限定的な適用、 大規模なエピジェネティックデータの管理に伴うデータプライバシーの懸念とセキュリティの問題）、機会（エピジェネティクスの応用拡大、人工知能と機械学習アルゴリズムの統合）、課題（抗体の品質に関する懸念、エピジェネティクス編集に関連する課題、標的外効果）がエピジェネティクス市場の成長に影響を与えています。
- 製品開発/イノベーション： エピジェネティクス市場の新しく発売された製品に関する詳細な洞察を記載しています。
- 市場開発： 有利な市場に関する包括的な情報 - 当レポートでは、様々な地域にわたるエピジェネティクス市場を分析しています。
- 市場の多様化： エピジェネティクス市場における新サービス、未開拓の地域、最近の開発、投資に関する網羅的な情報を提供します。
- 競合評価： Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US) and Qiagen (Germany)などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価しています。

1.　イントロダクション
2.　調査方法
3.　エグゼクティブサマリー
4.　プレミアムインサイト
5.　市場概要
6.　世界のエピジェネティクス市場規模：製品・サービス別
7.　世界のエピジェネティクス市場規模：方法別
8.　世界のエピジェネティクス市場規模：技術別
9.　世界のエピジェネティクス市場規模：用途別
10.　世界のエピジェネティクス市場規模：エンドユーザー別
11.　世界のエピジェネティクス市場規模：地域別
12.　競争環境
13.　企業情報
14.　付録

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 INTRODUCTION 44
1.1 STUDY OBJECTIVES 44
1.2 MARKET DEFINITION 44
1.2.1 INCLUSIONS & EXCLUSIONS 45
1.3 MARKET SCOPE 45
1.3.1 MARKETS COVERED 45
1.3.2 YEARS CONSIDERED 46
1.3.3 CURRENCY CONSIDERED 46
1.4 RESEARCH LIMITATIONS 46
1.5 STAKEHOLDERS 47
1.6 SUMMARY OF CHANGES 47
1.7 RECESSION IMPACT 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
FIGURE 1 RESEARCH DESIGN 49
2.1.1 SECONDARY DATA 50
2.1.2 PRIMARY DATA 51
FIGURE 2 BREAKDOWN OF PRIMARIES 51
2.2 MARKET SIZE ESTIMATION 52
FIGURE 3 MARKET SIZE ESTIMATION: EPIGENETICS MARKET (2022) 52
FIGURE 4 APPROACH 1: REVENUE SHARE ANALYSIS 53
FIGURE 5 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC.: EPIGENETICS MARKET (2022) 53
2.2.1 PRIMARY INSIGHTS 54
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 54
2.2.2 SEGMENTAL ASSESSMENT: EPIGENETICS MARKET 55
FIGURE 7 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 55
2.3 GROWTH RATE ASSUMPTIONS 56
FIGURE 8 CAGR PROJECTION: EPIGENETICS MARKET 56
FIGURE 9 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 57
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 58
FIGURE 10 DATA TRIANGULATION METHODOLOGY 58
2.5 STUDY ASSUMPTIONS 59
2.6 RISK ANALYSIS 59
 
2.7 RECESSION IMPACT: EPIGENETICS MARKET 59
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2028 (% GROWTH) 60
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 60
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 60
3 EXECUTIVE SUMMARY 61
FIGURE 11 EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 61
FIGURE 12 EPIGENETICS MARKET, BY METHOD, 2023 VS. 2028 (USD MILLION) 62
FIGURE 13 EPIGENETICS MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION) 62
FIGURE 14 EPIGENETICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 63
FIGURE 15 EPIGENETICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 63
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF EPIGENETICS MARKET 64
4 PREMIUM INSIGHTS 65
4.1 EPIGENETICS MARKET OVERVIEW 65
FIGURE 17 DECLINING SEQUENCING COSTS & TIME TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 65
4.2 NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 66
FIGURE 18 KITS & REAGENTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN EPIGENETICS MARKET IN 2022 66
4.3 EPIGENETICS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028 67
FIGURE 19 KITS & REAGENTS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2028 67
4.4 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATES FROM 2023 TO 2028 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
FIGURE 21 EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
TABLE 4 IMPACT ANALYSIS: EPIGENETICS MARKET 69
5.2.1 DRIVERS 69
5.2.1.1 Growing investments in research & development 69
5.2.1.2 Declining sequencing costs & time 70
FIGURE 22 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2020 71
5.2.1.3 Favorable government initiatives and funding for epigenetics research 72
5.2.1.4 Technological advancements in epigenetics research 72
5.2.1.5 Rising demand for epigenetic-based therapeutics 73
FIGURE 23 NUMBER OF CANCER CASES IN US, 2017–2022 74
 
5.2.2 RESTRAINTS 74
5.2.2.1 Limited applications of epigenomic data in toxicology 74
5.2.2.2 Data privacy concerns and security issues 75
5.2.3 OPPORTUNITIES 75
5.2.3.1 Expanding applications of epigenetics 75
5.2.3.2 Integration of artificial intelligence and machine learning algorithms 76
5.2.4 CHALLENGES 76
5.2.4.1 Concerns regarding quality of antibodies 76
5.2.4.2 Challenges associated with epigenetic editing 77
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
FIGURE 24 REVENUE SHIFT AND NEW REVENUE POCKETS FOR EPIGENETICS PROVIDERS 77
5.4 PRICING ANALYSIS 78
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER 78
TABLE 5 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER 78
5.4.2 AVERAGE SELLING PRICE TREND 79
5.5 TECHNOLOGY ANALYSIS 79
5.6 VALUE CHAIN ANALYSIS 80
FIGURE 25 VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 80
5.7 ECOSYSTEM MAP 81
FIGURE 26 ECOSYSTEM MAP 81
TABLE 6 ROLE IN ECOSYSTEM: EPIGENETICS MARKET 81
5.8 REGULATORY ANALYSIS 83
TABLE 7 KEY REGULATORY AGENCIES 83
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 12 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 13 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
5.9 PORTER’S FIVE FORCES ANALYSIS 88
TABLE 14 PORTER’S FIVE FORCES ANALYSIS: EPIGENETICS MARKET 88
5.9.1 THREAT OF NEW ENTRANTS 88
5.9.2 THREAT OF SUBSTITUTES 89
 
5.9.3 BARGAINING POWER OF SUPPLIERS 89
5.9.4 BARGAINING POWER OF BUYERS 89
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 89
5.10 PATENT ANALYSIS 90
FIGURE 27 PATENT APPLICATIONS FOR EPIGENETICS, NOVEMBER 2013–NOVEMBER 2023 90
TABLE 15 INDICATIVE LIST OF PATENTS: EPIGENETICS MARKET 90
5.11 KEY CONFERENCES & EVENTS 91
TABLE 16 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2023–2024 91
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 92
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 92
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EPIGENETICS 92
5.12.2 BUYING CRITERIA FOR EPIGENETICS 93
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 93
6 EPIGENETICS MARKET, BY PRODUCT & SERVICE 94
6.1 INTRODUCTION 95
TABLE 17 EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 95
6.2 KITS & REAGENTS 95
TABLE 18 EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 96
TABLE 19 EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 20 NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 21 EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 22 ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 23 LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.2.1 ANTIBODIES 98
6.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel growth 98
TABLE 24 EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 25 NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 26 EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 27 ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 28 LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 101
 
6.2.2 CHIP-SEQUENCING KITS & REAGENTS 101
6.2.2.1 Versatile applications of chromatin immunoprecipitation (ChIP) pertaining to epigenetic regulatory systems to boost demand 101
TABLE 29 EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 30 NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 31 EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 32 ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 33 LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 104
6.2.3 BISULFITE CONVERSION KITS & REAGENTS 104
6.2.3.1 Effective outcomes associated with bisulfite conversion to drive demand 104
TABLE 34 EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION) 105
TABLE 35 NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 36 EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 37 ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 38 LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 107
6.2.4 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS 107
6.2.4.1 Ability of whole-genome amplification to maintain relative proportions of genes in original pool to drive adoption 107
TABLE 39 EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 40 NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 41 EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 42 ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 43 LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.2.5 5-HMC & 5-MC ANALYSIS KITS & REAGENTS 110
6.2.5.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth 110
TABLE 44 EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 45 NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 46 EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 47 ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 48 LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 113
6.2.6 HISTONES 113
6.2.6.1 Emerging importance of chromatin-associated proteins and histones in epigenetic research to drive segmental growth 113
TABLE 49 EPIGENETICS MARKET FOR HISTONES, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 50 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 51 EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 52 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 53 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2021–2028 (USD MILLION) 116
6.2.7 OTHER KITS & REAGENTS 116
TABLE 54 EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 55 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 56 EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 57 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 58 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION) 119
6.3 ENZYMES 119
TABLE 59 EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 60 EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 61 NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 62 EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 63 ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 64 LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 121
6.3.1 DNA-MODIFYING ENZYMES 121
6.3.1.1 Broadening applications of DNA methylation to favor market growth 121
TABLE 65 EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY REGION, 2021–2028 (USD MILLION) 122
TABLE 66 NORTH AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 67 EUROPE: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 68 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 69 LATIN AMERICA: EPIGENETICS MARKET FOR DNA-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 124
6.3.2 PROTEIN-MODIFYING ENZYMES 124
6.3.2.1 Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to drive segmental growth 124
TABLE 70 EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 71 NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 72 EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 73 ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 74 LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 127
6.3.3 OTHER ENZYMES 127
TABLE 75 EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 76 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 77 EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 78 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 79 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 129
6.4 INSTRUMENTS & ACCESSORIES 129
6.4.1 WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO PROPEL GROWTH 129
TABLE 80 EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 81 NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 82 EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 83 ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 84 LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2021–2028 (USD MILLION) 132
6.5 SOFTWARE 132
6.5.1 DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION AND RNA ANALYSIS TO PROPEL GROWTH 132
TABLE 85 EPIGENETICS MARKET FOR SOFTWARE, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 86 NORTH AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 87 EUROPE: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 88 ASIA PACIFIC: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 89 LATIN AMERICA: EPIGENETICS MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 135
6.6 SERVICES 135
6.6.1 EXPANDING POOL OF SERVICE PROVIDERS TO DRIVE GROWTH 135
TABLE 90 EPIGENETICS MARKET FOR SERVICES, BY REGION, 2021–2028 (USD MILLION) 136
TABLE 91 NORTH AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 92 EUROPE: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 93 ASIA PACIFIC: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 94 LATIN AMERICA: EPIGENETICS MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 138
7 EPIGENETICS MARKET, BY METHOD 139
7.1 INTRODUCTION 140
TABLE 95 EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 140
7.2 DNA METHYLATION 140
7.2.1 INCREASING R&D ACTIVITIES TO EXPLORE POTENTIAL OF DNA METHYLATION TO DRIVE MARKET GROWTH 140
TABLE 96 EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 97 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 98 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 99 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 100 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2021–2028 (USD MILLION) 143
7.3 HISTONE MODIFICATIONS 143
7.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE SEGMENTAL GROWTH 143
TABLE 101 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS 144
TABLE 102 EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 103 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 104 EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 105 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 106 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 146
7.4 OTHER METHODS 146
TABLE 107 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2021–2028 (USD MILLION) 147
TABLE 108 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 109 EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 110 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 111 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2021–2028 (USD MILLION) 149
8 EPIGENETICS MARKET, BY TECHNIQUE 150
8.1 INTRODUCTION 151
TABLE 112 EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 151
8.2 NGS 151
8.2.1 ABILITY TO OFFER COMPREHENSIVE EPIGENETIC PROFILES TO PROPEL DEMAND FOR NGS TECHNIQUE 151
TABLE 113 EPIGENETICS MARKET FOR NGS, BY REGION, 2021–2028 (USD MILLION) 152
TABLE 114 NORTH AMERICA: EPIGENETICS MARKET FOR NGS, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 115 EUROPE: EPIGENETICS MARKET FOR NGS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 116 ASIA PACIFIC: EPIGENETICS MARKET FOR NGS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 117 LATIN AMERICA: EPIGENETICS MARKET FOR NGS, BY COUNTRY, 2021–2028 (USD MILLION) 154
8.3 PCR & QPCR 154
8.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE GROWTH 154
TABLE 118 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 119 NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 120 EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 121 ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 122 LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2021–2028 (USD MILLION) 157
8.4 MASS SPECTROMETRY 157
8.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET 157
TABLE 123 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2021–2028 (USD MILLION) 158
TABLE 124 NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 125 EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 126 ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 127 LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2021–2028 (USD MILLION) 160
8.5 SONICATION 160
8.5.1 INTRODUCTION OF IMPROVED HIGH-THROUGHPUT SONICATION TECHNIQUES TO PROPEL ADOPTION 160
TABLE 128 EPIGENETICS MARKET FOR SONICATION, BY REGION, 2021–2028 (USD MILLION) 161
TABLE 129 NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 130 EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 131 ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 132 LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2021–2028 (USD MILLION) 163
8.6 OTHER TECHNIQUES 163
TABLE 133 EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2021–2028 (USD MILLION) 164
TABLE 134 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 135 EUROPE: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 136 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 137 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021–2028 (USD MILLION) 166
9 EPIGENETICS MARKET, BY APPLICATION 167
9.1 INTRODUCTION 168
TABLE 138 EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 168
9.2 ONCOLOGY 168
9.2.1 GROWING EFFORTS TO DEVELOP ONCOLOGY EPIGENETIC DRUGS TO BOOST MARKET 168
TABLE 139 EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS 169
TABLE 140 EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 171
TABLE 141 NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 142 EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 143 ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 144 LATIN AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 173
9.3 METABOLIC DISEASES 173
9.3.1 EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT TO FAVOR MARKET GROWTH 173
TABLE 145 EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION, 2021–2028 (USD MILLION) 174
TABLE 146 NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 147 EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 148 ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 149 LATIN AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 176
9.4 IMMUNOLOGY 176
9.4.1 GROWING DEMAND FOR EPIGENETIC PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO SUPPORT GROWTH 176
TABLE 150 EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 151 NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 152 EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 153 ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 154 LATIN AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 179
9.5 DEVELOPMENTAL BIOLOGY 179
9.5.1 INCREASING RESEARCH IN DEVELOPMENTAL BIOLOGY TO PROPEL GROWTH 179
TABLE 155 EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION, 2021–2028 (USD MILLION) 180
TABLE 156 NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 157 EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 158 ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 159 LATIN AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
11.3 NORTH AMERICA: RECESSION IMPACT 213 182
9.6 CARDIOVASCULAR DISEASES 182
9.6.1 EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING ETIOLOGY OF CARDIOVASCULAR DISEASES TO BOOST ADOPTION 182
TABLE 160 EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION) 183
TABLE 161 NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 162 EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 163 ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 164 LATIN AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 185
9.7 OTHER APPLICATIONS 185
TABLE 165 EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 186
TABLE 166 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 167 EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 187
TABLE 168 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 187
TABLE 169 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 188
10 EPIGENETICS MARKET, BY END USER 189
10.1 INTRODUCTION 190
TABLE 170 EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 190
10.2 ACADEMIC & RESEARCH INSTITUTES 190
10.2.1 INCREASING GOVERNMENT INVESTMENTS & COLLABORATIONS TO CONTRIBUTE TO MARKET GROWTH 190
TABLE 171 EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 191
TABLE 172 NORTH AMERICA: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 191
TABLE 173 EUROPE: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 192
TABLE 174 ASIA PACIFIC: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 192
TABLE 175 LATIN AMERICA: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 193
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 193
10.3.1 GROWING NUMBER OF CLINICAL TRIALS FOR EPIGENETICS-BASED DRUGS TO DRIVE GROWTH 193
TABLE 176 EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 194
TABLE 177 NORTH AMERICA: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 178 EUROPE: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 195
TABLE 179 ASIA PACIFIC: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 195
TABLE 180 LATIN AMERICA: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 196
10.4 HOSPITALS & CLINICS 196
10.4.1 GROWING IMPORTANCE OF MEASUREMENT OF DNA METHYLATION IN HOSPITAL SETTINGS TO BOOST MARKET 196
TABLE 181 EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2021–2028 (USD MILLION) 197
TABLE 182 NORTH AMERICA: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 183 EUROPE: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 198
TABLE 184 ASIA PACIFIC: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 198
TABLE 185 LATIN AMERICA: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 199
11 EPIGENETICS MARKET, BY REGION 200
11.1 INTRODUCTION 201
TABLE 186 EPIGENETICS MARKET, BY REGION, 2021–2028 (USD MILLION) 201
11.2 NORTH AMERICA 201
FIGURE 30 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT 202
TABLE 187 NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 188 NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 203
TABLE 189 NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 203
TABLE 190 NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 204
TABLE 191 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 204
TABLE 192 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 204
TABLE 193 NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 205
TABLE 194 NORTH AMERICA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 205
11.2.1 US 205
11.2.1.1 Strong network of well-established epigenetic product manufacturers to drive market growth 205
TABLE 195 US: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 206
TABLE 196 US: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 197 US: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 207
TABLE 198 US: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 208
TABLE 199 US: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 208
TABLE 200 US: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 209
TABLE 201 US: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 209
 
11.2.2 CANADA 209
11.2.2.1 Increasing government initiatives to boost epigenetics research 209
TABLE 202 CANADA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 210
TABLE 203 CANADA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 204 CANADA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 211
TABLE 205 CANADA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 212
TABLE 206 CANADA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 212
TABLE 207 CANADA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 213
TABLE 208 CANADA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 213
11.3 NORTH AMERICA: RECESSION IMPACT 213

11.4 EUROPE 214
TABLE 209 EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 214
TABLE 210 EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 215
TABLE 211 EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 215
TABLE 212 EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 213 EUROPE: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 216
TABLE 214 EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 216
TABLE 215 EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 217
TABLE 216 EUROPE: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 217
11.4.1 GERMANY 217
11.4.1.1 Significant investments in NGS to boost adoption of epigenetics products 217
TABLE 217 GERMANY: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 218
TABLE 218 GERMANY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 219 GERMANY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 220 GERMANY: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 220
TABLE 221 GERMANY: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 220
TABLE 222 GERMANY: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 220
TABLE 223 GERMANY: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 221
 
11.4.2 UK 221
11.4.2.1 Rising acceptance of genome-based diagnostic techniques by clinicians to support growth 221
TABLE 224 UK: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 222
TABLE 225 UK: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 226 UK: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 223
TABLE 227 UK: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 223
TABLE 228 UK: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 223
TABLE 229 UK: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 224
TABLE 230 UK: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 224
11.4.3 FRANCE 224
11.4.3.1 Growing demand for PCR technologies to propel market growth 224
TABLE 231 FRANCE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 225
TABLE 232 FRANCE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 233 FRANCE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 226
TABLE 234 FRANCE: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 226
TABLE 235 FRANCE: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 226
TABLE 236 FRANCE: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 227
TABLE 237 FRANCE: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 227
11.4.4 ITALY 227
11.4.4.1 High incidence of cancer to support market growth 227
TABLE 238 ITALY: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 228
TABLE 239 ITALY: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 240 ITALY: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 241 ITALY: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 229
TABLE 242 ITALY: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 229
TABLE 243 ITALY: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 230
TABLE 244 ITALY: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 230
11.4.5 SPAIN 230
11.4.5.1 Well-established network of research centers and universities to boost market 230
TABLE 245 SPAIN: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 231
TABLE 246 SPAIN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 247 SPAIN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 248 SPAIN: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 232
TABLE 249 SPAIN: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 232
TABLE 250 SPAIN: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 233
TABLE 251 SPAIN: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 233
11.4.6 REST OF EUROPE 233
TABLE 252 REST OF EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 234
TABLE 253 REST OF EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 254 REST OF EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 255 REST OF EUROPE: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 235
TABLE 256 REST OF EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 235
TABLE 257 REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 236
TABLE 258 REST OF EUROPE: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 236
11.5 EUROPE: RECESSION IMPACT 236
11.6 ASIA PACIFIC 237
FIGURE 31 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT 238
TABLE 259 ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 239
TABLE 260 ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 239
TABLE 261 ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 240
TABLE 262 ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 240
TABLE 263 ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 241
TABLE 264 ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 241
TABLE 265 ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 242
TABLE 266 ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 242
11.6.1 JAPAN 242
11.6.1.1 Increasing collaborations between research & academic organizations to favor market growth 242
TABLE 267 JAPAN: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 243
TABLE 268 JAPAN: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 269 JAPAN: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 270 JAPAN: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 245
TABLE 271 JAPAN: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 245
TABLE 272 JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 246
TABLE 273 JAPAN: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 246
11.6.2 CHINA 246
11.6.2.1 High demand for personalized medicine to fuel growth 246
TABLE 274 CHINA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 247
TABLE 275 CHINA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 276 CHINA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 277 CHINA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 249
TABLE 278 CHINA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 249
TABLE 279 CHINA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 250
TABLE 280 CHINA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 250
11.6.3 INDIA 250
11.6.3.1 Expanding base of biotechnology facilities to drive growth 250
TABLE 281 INDIA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 251
TABLE 282 INDIA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 252
TABLE 283 INDIA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 252
TABLE 284 INDIA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 253
TABLE 285 INDIA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 253
TABLE 286 INDIA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 254
TABLE 287 INDIA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 254
11.6.4 SOUTH KOREA 254
11.6.4.1 Increasing demand for epigenetic testing to boost growth 254
TABLE 288 SOUTH KOREA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 255
TABLE 289 SOUTH KOREA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 290 SOUTH KOREA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 291 SOUTH KOREA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 256
TABLE 292 SOUTH KOREA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 256
TABLE 293 SOUTH KOREA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 257
TABLE 294 SOUTH KOREA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 257
11.6.5 REST OF ASIA PACIFIC 257
TABLE 295 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 258
TABLE 296 REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 297 REST OF ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 298 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 259
TABLE 299 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 259
TABLE 300 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 260
TABLE 301 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 260
11.6.6 ASIA PACIFIC: RECESSION IMPACT 260
11.7 LATIN AMERICA 261
TABLE 302 LATIN AMERICA: EPIGENETICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 261
TABLE 303 LATIN AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 262
TABLE 304 LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 262
TABLE 305 LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 306 LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 263
TABLE 307 LATIN AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 263
TABLE 308 LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 264
TABLE 309 LATIN AMERICA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 264
11.7.1 BRAZIL 264
11.7.1.1 Increasing number of healthcare providers incorporating epigenetic testing to boost growth 264
TABLE 310 BRAZIL: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 265
TABLE 311 BRAZIL: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 265
TABLE 312 BRAZIL: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 266
TABLE 313 BRAZIL: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 266
TABLE 314 BRAZIL: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 266
TABLE 315 BRAZIL: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 267
TABLE 316 BRAZIL: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 267
11.7.2 MEXICO 267
11.7.2.1 Growing adoption of cutting-edge technologies to support growth 267
TABLE 317 MEXICO: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 268
TABLE 318 MEXICO: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 319 MEXICO: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 320 MEXICO: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 269
TABLE 321 MEXICO: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 269
TABLE 322 MEXICO: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 270
TABLE 323 MEXICO: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 270
11.7.3 REST OF LATIN AMERICA 270
TABLE 324 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 271
TABLE 325 REST OF LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 271
TABLE 326 REST OF LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 327 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 272
TABLE 328 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 272
TABLE 329 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 273
TABLE 330 REST OF LATIN AMERICA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 273
11.7.4 LATIN AMERICA: RECESSION IMPACT 273
11.8 MIDDLE EAST 274
11.8.1 INCREASE IN FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO BOOST GROWTH 274
TABLE 331 MIDDLE EAST: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 274
TABLE 332 MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 275
TABLE 333 MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 275
TABLE 334 MIDDLE EAST: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 276
TABLE 335 MIDDLE EAST: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 276
TABLE 336 MIDDLE EAST: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 277
TABLE 337 MIDDLE EAST: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 277
11.8.2 MIDDLE EAST: RECESSION IMPACT 277
 
11.9 AFRICA 278
11.9.1 GROWING COLLABORATIONS TO SUPPORT GROWTH IN COMING YEARS 278
TABLE 338 AFRICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 278
TABLE 339 AFRICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021–2028 (USD MILLION) 279
TABLE 340 AFRICA: EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2021–2028 (USD MILLION) 279
TABLE 341 AFRICA: EPIGENETICS MARKET, BY METHOD, 2021–2028 (USD MILLION) 280
TABLE 342 AFRICA: EPIGENETICS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 280
TABLE 343 AFRICA: EPIGENETICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 281
TABLE 344 AFRICA: EPIGENETICS MARKET, BY END USER, 2021–2028 (USD MILLION) 281
11.9.2 AFRICA: RECESSION IMPACT 281
12 COMPETITIVE LANDSCAPE 282
12.1 INTRODUCTION 282
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 283
FIGURE 32 EPIGENETICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 283
12.3 REVENUE ANALYSIS 284
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 284
12.4 MARKET SHARE ANALYSIS 284
FIGURE 34 EPIGENETICS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 285
TABLE 345 EPIGENETICS MARKET: DEGREE OF COMPETITION 285
12.5 COMPANY EVALUATION MATRIX 286
12.5.1 STARS 286
12.5.2 EMERGING LEADERS 287
12.5.3 PERVASIVE PLAYERS 287
12.5.4 PARTICIPANTS 287
FIGURE 35 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX, 2022 288
12.5.5 COMPANY FOOTPRINT ANALYSIS 289
TABLE 346 EPIGENETICS MARKET: PRODUCT FOOTPRINT ANALYSIS 289
TABLE 347 EPIGENETICS MARKET: REGIONAL FOOTPRINT ANALYSIS 290
12.6 START-UP/SME EVALUATION QUADRANT 291
12.6.1 PROGRESSIVE COMPANIES 291
12.6.2 RESPONSIVE COMPANIES 291
12.6.3 DYNAMIC COMPANIES 291
12.6.4 STARTING BLOCKS 291
FIGURE 36 EPIGENETICS MARKET: START-UP/SME EVALUATION MATRIX, 2022 292
12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 293
TABLE 348 EPIGENETICS MARKET: DETAILS OF START-UP/SME PLAYERS 293
TABLE 349 EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS 294
 
12.7 COMPETITIVE SCENARIO & TRENDS 294
12.7.1 PRODUCT LAUNCHES & APPROVALS 294
TABLE 350 EPIGENETICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2023 294
12.7.2 DEALS 295
TABLE 351 EPIGENETICS MARKET: DEALS, JANUARY 2021–SEPTEMBER 2023 295
12.7.3 OTHER DEVELOPMENTS 296
TABLE 352 EPIGENETICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2023 296
13 COMPANY PROFILES 297
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 KEY MARKET PLAYERS 297
13.1.1 THERMO FISHER SCIENTIFIC INC. 297
TABLE 353 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 297
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 298
13.1.2 ILLUMINA, INC. 301
TABLE 354 ILLUMINA, INC.: BUSINESS OVERVIEW 301
FIGURE 38 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 302
13.1.3 MERCK KGAA 305
TABLE 355 MERCK KGAA: BUSINESS OVERVIEW 305
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2022) 306
13.1.4 PACBIO 309
TABLE 356 PACBIO: BUSINESS OVERVIEW 309
FIGURE 40 PACBIO: COMPANY SNAPSHOT (2022) 310
13.1.5 ABCAM PLC 313
TABLE 357 ABCAM PLC: BUSINESS OVERVIEW 313
FIGURE 41 ABCAM PLC: COMPANY SNAPSHOT (2022) 314
13.1.6 BIO-RAD LABORATORIES, INC. 317
TABLE 358 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 317
FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 318
13.1.7 ACTIVE MOTIF INC. 322
TABLE 359 ACTIVE MOTIF INC.: BUSINESS OVERVIEW 322
13.1.8 NEW ENGLAND BIOLABS 326
TABLE 360 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW 326
13.1.9 QIAGEN 329
TABLE 361 QIAGEN: BUSINESS OVERVIEW 329
FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2022) 330
13.1.10 ZYMO RESEARCH CORPORATION 332
TABLE 362 ZYMO RESEARCH CORPORATION: BUSINESS OVERVIEW 332
 
13.1.11 REVVITY 335
TABLE 363 REVVITY: BUSINESS OVERVIEW 335
FIGURE 44 REVVITY: COMPANY SNAPSHOT (2022) 336
13.1.12 DIAGENODE SA (A HOLOGIC COMPANY) 338
TABLE 364 DIAGENODE SA (A HOLOGIC COMPANY): BUSINESS OVERVIEW 338
13.1.13 F. HOFFMANN-LA ROCHE LTD. 341
TABLE 365 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 341
FIGURE 45 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 342
13.1.14 PROMEGA CORPORATION 343
TABLE 366 PROMEGA CORPORATION: BUSINESS OVERVIEW 343
13.1.15 EPIGENTEK GROUP INC. 345
TABLE 367 EPIGENTEK GROUP INC.: BUSINESS OVERVIEW 345
13.2 OTHER PLAYERS 349
13.2.1 EPICYPHER 349
13.2.2 FIOS GENOMICS 350
13.2.3 GENOMESCAN 351
13.2.4 CREATIVE BIOGENE 352
13.2.5 BPS BIOSCIENCE, INC. 353
13.2.6 ABNOVA CORPORATION 354
13.2.7 CREATIVE DIAGNOSTICS 355
13.2.8 BIOMODAL (FORMERLY CAMBRIDGE EPIGENETIX) 356
13.2.9 INTEGRATED DNA TECHNOLOGIES, INC. 356
13.2.10 NOVOGENE CO., LTD. 358
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX 359
14.1 DISCUSSION GUIDE 359
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 363
14.3 CUSTOMIZATION OPTIONS 365
14.4 RELATED REPORTS 365
14.5 AUTHOR DETAILS 366

★調査レポート[世界のエピジェネティクス市場（～2028年）：製品・サービス別（酵素（DNA修飾酵素）、キット・試薬（抗体）、機器、ソフトウェア）、方法別（DNAメチル化）、技術別（NGS、PCR、質量分析）、用途別（腫瘍学、免疫学）] (コード：BT2775-24)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のエピジェネティクス市場（～2028年）：製品・サービス別（酵素（DNA修飾酵素）、キット・試薬（抗体）、機器、ソフトウェア）、方法別（DNAメチル化）、技術別（NGS、PCR、質量分析）、用途別（腫瘍学、免疫学）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のフローサイトメトリー市場（～2028年）：技術別（細胞ベース、ビーズベース）、製品＆サービス別（分析装置、選別機、消耗品、ソフトウェア）、用途別（研究-免疫学、幹細胞、臨床-血液学）、エンドユーザー別、地域別
  • 世界のゲノミクス市場（～2028年）：製品＆サービス別（消耗品、機器、システム＆ソフトウェア）、技術別（シーケンス、PCR、マイクロアレイ）、研究タイプ別（エピゲノム、バイオマーカー探索）、用途別（創薬、診断、農業）
  • 世界のラベルフリー検出市場（～2028年）：製品＆サービス別（機器、消耗品（バイオセンサーチップ、マイクロプレート）、ソフトウェア）、技術別（表面プラズモン共鳴（SPR））、用途別（ヒット確認、リード生成）、エンドユーザー別（製薬、CRO）、地域別
  • 世界の遺伝子編集市場（～2028年）：製品＆サービス別（試薬、消耗品、システム、ソフトウェア）、技術別（CRISPR、TALEN、ZFN、アンチセンス）、用途別（細胞株工学、遺伝子工学、創薬）、エンドユーザー別（製薬、バイオテクノロジー）
  • 世界の臨床試験用画像市場（2023-2033)：ソフトウェア・サービス別（ソフトウェア、サービス）、モダリティ別（コンピューター断層撮影、磁気共鳴画像診断、超音波診断、その他）、治療領域別（腫瘍、感染症、神経内科、CVS）、エンドユーザー別（製薬企業、バイオテクノロジー企業、医療機器メーカー、その他）、地域別
  • 世界のバイオマーカー市場（～2028）：製品＆サービス別（消耗品、サービス、ソフトウェア）、種類別（安全性、有効性、検証）、疾患別（癌、感染症、神経）、用途別（診断、創薬、個別化医療）、地域別
  • 世界の体外診断（IVD）市場（～2027年）：製品＆サービス別（機器、キット、ソフトウェア）、技術別（免疫測定、血液検査、尿検査）、用途別（糖尿病、腫瘍、循環器、感染症）、エンドユーザー別（病院、診療所）
  • 世界の細胞解析市場2023-2030：技術別（フローサイトメトリー、質量分析、次世代シーケンシング（NGS）、ポリメラーゼ連鎖反応（PCR）、その他）、用途別（腫瘍学、免疫学、心臓病学、遺伝子疾患、幹細胞、その他）、製品別（消耗品、サービス、機器、ソフトウェア）、エンドユーザー別（バイオテクノロジー＆製薬会社、病院＆診断研究所、学術＆研究所、その他）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆